Clinical & Experimental Metastasis最新文献_第8页

Stereotactic body radiotherapy for spinal oligometastases: a survey on patterns of practice on behalf of the Italian Association of Clinical Oncology and Radiotherapy (AIRO). 脊柱少见转移灶的立体定向体放射治疗：代表意大利临床肿瘤学和放射治疗协会（AIRO）进行的实践模式调查。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-10-01 Epub Date: 2024-08-01 DOI: 10.1007/s10585-024-10304-3

Francesco Cuccia, Ciro Franzese, Serena Badellino, Paolo Borghetti, Manuela Federico, Giulia Marvaso, Giampaolo Montesi, Antonio Pontoriero, Giuseppe Ferrera, Filippo Alongi, Marta Scorsetti

{"title":"Stereotactic body radiotherapy for spinal oligometastases: a survey on patterns of practice on behalf of the Italian Association of Clinical Oncology and Radiotherapy (AIRO).","authors":"Francesco Cuccia, Ciro Franzese, Serena Badellino, Paolo Borghetti, Manuela Federico, Giulia Marvaso, Giampaolo Montesi, Antonio Pontoriero, Giuseppe Ferrera, Filippo Alongi, Marta Scorsetti","doi":"10.1007/s10585-024-10304-3","DOIUrl":"10.1007/s10585-024-10304-3","url":null,"abstract":"Background: The Study Group for the Biology and Treatment of the OligoMetastatic Disease on behalf of the Italian Association of Radiotherapy and Clinical Oncology (AIRO) has conducted a national survey with the aim to depict the current patterns of practice of stereotactic body radiotherapy (SBRT) for spinal oligometastases.Methods: The Surveymonkey platform was used to send a 28-items questionnaire focused on demographic, clinical and technical aspects related to SBRT for spinal oligometastases. All the AIRO members were invited to fill the questionnaire. Data were then centralized to a single center for analysis and interpretation.Results: 53 radiation oncologists from 47 centers fulfilled the survey. A complete agreement was observed in proposing SBRT for spinal oligometastases, with the majority considering up to 3 concurrent spine oligometastases feasible for SBRT (73.5%), regardless of spine site (70%), vertebral segment (85%) and morphological features of the lesion (71.7%). Regarding dose prescription, fractionated regimens resulted as the preferred option, either in 3 (58.4%) or five sessions (34%), with a substantial agreement in applying a PTV-margin larger than 1 mm (almost 90% of participants), and ideally using both MRI and PET imaging to improve target volume and organs-at-risk delineation (67.9%).Conclusions: This national italian survey illustrates the patterns of practice and the main issues for the indication of SBRT for spinal oligometastases. A substantial agreement in the numerical cut-off and vertebral segment involved for SBRT indication was reported, with a slight heterogeneity in terms of dose prescription and fractionation schemes.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":" ","pages":"679-685"},"PeriodicalIF":4.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141859201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Targeting CD44 and other pleiotropic co-receptors as a means for broad inhibition of tumor growth and metastasis. 以 CD44 和其他多效应共受体为靶点，广泛抑制肿瘤生长和转移。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-10-01 Epub Date: 2024-05-18 DOI: 10.1007/s10585-024-10292-4

Lisa-Marie Mehner, Leonel Munoz-Sagredo, Steffen Joachim Sonnentag, Sven Máté Treffert, Véronique Orian-Rousseau

{"title":"Targeting CD44 and other pleiotropic co-receptors as a means for broad inhibition of tumor growth and metastasis.","authors":"Lisa-Marie Mehner, Leonel Munoz-Sagredo, Steffen Joachim Sonnentag, Sven Máté Treffert, Véronique Orian-Rousseau","doi":"10.1007/s10585-024-10292-4","DOIUrl":"10.1007/s10585-024-10292-4","url":null,"abstract":"Although progress has been made in the treatment of cancer, particularly for the four major types of cancers affecting the lungs, colon, breast and prostate, resistance to cancer treatment often emerges upon inhibition of major signaling pathways, which leads to the activation of additional pathways as a last-resort survival mechanism by the cancer cells. This signaling plasticity provides cancer cells with a level of operational freedom, reducing treatment efficacy. Plasticity is a characteristic of cancer cells that are not only able to switch signaling pathways but also from one cellular state (differentiated cells to stem cells or vice versa) to another. It seems implausible that the inhibition of one or a few signaling pathways of heterogeneous and plastic tumors can sustain a durable effect. We propose that inhibiting molecules with pleiotropic functions such as cell surface co-receptors can be a key to preventing therapy escape instead of targeting bona fide receptors. Therefore, we ask the question whether co-receptors often considered as \"accessory molecules\" are an overlooked key to control cancer cell behavior.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":" ","pages":"599-611"},"PeriodicalIF":4.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11499327/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140956499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A clinical-radiomics nomogram based on spectral CT multi-parameter images for preoperative prediction of lymph node metastasis in colorectal cancer. 基于光谱 CT 多参数图像的临床放射组学提名图，用于术前预测结直肠癌淋巴结转移。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-10-01 Epub Date: 2024-05-20 DOI: 10.1007/s10585-024-10293-3

Qian Li, Rui Hong, Ping Zhang, Liting Hou, Hailun Bao, Lin Bai, Jian Zhao

{"title":"A clinical-radiomics nomogram based on spectral CT multi-parameter images for preoperative prediction of lymph node metastasis in colorectal cancer.","authors":"Qian Li, Rui Hong, Ping Zhang, Liting Hou, Hailun Bao, Lin Bai, Jian Zhao","doi":"10.1007/s10585-024-10293-3","DOIUrl":"10.1007/s10585-024-10293-3","url":null,"abstract":"To develop a clinical-radiomics nomogram based on spectral CT multi-parameter images for predicting lymph node metastasis in colorectal cancer. A total of 76 patients with colorectal cancer and 156 lymph nodes were included. The clinical data of the patients were collected, including gender, age, tumor location and size, preoperative tumor markers, etc. Three sets of conventional images in the arterial, venous, and delayed phases were obtained, and six sets of spectral images were reconstructed using the arterial phase spectral data, including virtual monoenergetic images (40 keV, 70 keV, 100 keV), iodine density maps, iodine no water maps, and virtual non-contrast images. Radiomics features of lymph nodes were extracted from the above images, respectively. Univariate analysis and least absolute shrinkage and selection operator (LASSO) regression were used to select features. A clinical model was constructed based on age and carcinoembryonic antigen (CEA) levels. The radiomics features selected were used to generate a composed radiomics signature (Com-RS). A nomogram was developed using age, CEA, and the Com-RS. The models' prediction efficiency, calibration, and clinical application value were evaluated by the area under the receiver operating characteristic curve (AUC), calibration curve, and decision curve analysis, respectively. The nomogram outperforms the clinical model and the Com-RS (AUC = 0.879, 0.824). It is well calibrated and has great clinical application value. This study developed a clinical-radiomics nomogram based on spectral CT multi-parameter images, which can be used as an effective tool for preoperative personalized prediction of lymph node metastasis in colorectal cancer.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":" ","pages":"639-653"},"PeriodicalIF":4.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141064551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Editorial: Cancer metastasis through the lymphovascular system: molecular mechanisms of cancer metastasis. 更正为社论：癌症通过淋巴管系统转移：癌症转移的分子机制。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-10-01 DOI: 10.1007/s10585-024-10287-1

Stanley P Leong, S David Nathanson, Jonathan S Zager

引用次数: 0

Correction: Predictive value of 18 F-FDG PET/CT versus bone marrow biopsy and aspiration in pediatric neuroblastoma. 更正：18 F-FDG PET/CT 与骨髓活检和抽吸术对小儿神经母细胞瘤的预测价值。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-10-01 DOI: 10.1007/s10585-024-10295-1

Zhenzhen Zhao, Chao Yang

引用次数: 0

Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2. Trastuzumab deruxtecan（DS-8201a）是一种 HER2 靶向抗体-药物共轭物，在体外和体内对过度表达 HER2 的原发性和转移性卵巢肿瘤具有抗肿瘤活性。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-10-01 Epub Date: 2024-06-22 DOI: 10.1007/s10585-024-10297-z

Levent Mutlu, Blair McNamara, Stefania Bellone, Diego D Manavella, Cem Demirkiran, Michelle Greenman, Miguel Skyler Z Verzosa, Natalia Buza, Pei Hui, Tobias Max Philipp Hartwich, Justin Harold, Yang Yang-Hartwich, Margherita Zipponi, Gary Altwerger, Elena Ratner, Gloria S Huang, Mitchell Clark, Vaagn Andikyan, Masoud Azodi, Peter E Schwartz, Alessandro D Santin

{"title":"Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2.","authors":"Levent Mutlu, Blair McNamara, Stefania Bellone, Diego D Manavella, Cem Demirkiran, Michelle Greenman, Miguel Skyler Z Verzosa, Natalia Buza, Pei Hui, Tobias Max Philipp Hartwich, Justin Harold, Yang Yang-Hartwich, Margherita Zipponi, Gary Altwerger, Elena Ratner, Gloria S Huang, Mitchell Clark, Vaagn Andikyan, Masoud Azodi, Peter E Schwartz, Alessandro D Santin","doi":"10.1007/s10585-024-10297-z","DOIUrl":"10.1007/s10585-024-10297-z","url":null,"abstract":"High-grade serous ovarian cancer (HGSOC) and ovarian clear cell carcinoma (CC), are biologically aggressive tumors endowed with the ability to rapidly metastasize to the abdominal cavity and distant organs. About 10% of HGSOC and 30% of CC demonstrate HER2 IHC 3 + receptor over-expression. We evaluated the efficacy of trastuzumab deruxtecan (T-DXd; DS-8201a), a novel HER2-targeting antibody-drug conjugate (ADC) to an ADC isotype control (CTL ADC) against multiple HGSOC and CC tumor models. Eleven ovarian cancer cell lines including a matched primary and metastatic cell line established from the same patient, were evaluated for HER2 expression by immunohistochemistry and flow cytometry, and gene amplification by fluorescence in situ hybridization assays. In vitro experiments demonstrated T-DXd to be significantly more effective against HER2 3 + HGSOC and CC cell lines when compared to CTL ADC (p < 0.0001). T-DXd induced efficient bystander killing of HER2 non-expressing tumor cells when admixed with HER2 3 + cells. In vivo activity of T-DXd was studied in HER2 IHC 3 + HGSOC and CC mouse xenograft models. We found T-DXd to be significantly more effective than CTL ADC against HER2 3 + HGSOC (KR(CH)31) and CC (OVA10) xenografts with a significant difference in tumor growth starting at day 8 (p = 0.0003 for KR(CH)31, p < 0.0001 for OVA10). T-DXd also conferred a survival advantage in both xenograft models. T-DXd may represent an effective ADC against primary and metastatic HER2-overexpressing HGSOC and CC.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":" ","pages":"765-775"},"PeriodicalIF":4.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141440225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Stereotactic radiotherapy for liver oligometastases: a pooled analysis following the estro/eortc consensus recommendations. 肝脏少见转移灶的立体定向放射治疗：根据estro/eortc共识建议进行的汇总分析。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-10-01 Epub Date: 2024-07-17 DOI: 10.1007/s10585-024-10301-6

D Pezzulla, G Chiloiro, E M Lima, G Macchia, C Romano, S Reina, G Panza, S Cilla, A G Morganti, F Cellini, M A Gambacorta, F Deodato

{"title":"Stereotactic radiotherapy for liver oligometastases: a pooled analysis following the estro/eortc consensus recommendations.","authors":"D Pezzulla, G Chiloiro, E M Lima, G Macchia, C Romano, S Reina, G Panza, S Cilla, A G Morganti, F Cellini, M A Gambacorta, F Deodato","doi":"10.1007/s10585-024-10301-6","DOIUrl":"10.1007/s10585-024-10301-6","url":null,"abstract":"A large pooled analysis of liver oligometastases, classified accordingly to the ESTRO/EORTC recommendations, treated by stereotactic radiotherapy (SBRT) and Radiosurgery (SRS) was carried out. The clinical and dosimetric data of patients who underwent SBRT/SRS for liver metastases were analysed in terms of efficacy and toxicity profile. In particular, the Local Control (LC), the Distant Metastases Free Survival (DMFS), the Disease-Free Survival (DFS), the Overall Survival (OS), and the Next Systemic Therapy Free Survival (NEST-FS) rates were analysed. 113 patients (M/F: 49/64), accounting for a total of 150 hepatic lesions (March 2006-February 2023) in two Italian radiotherapy Institutions were evaluated. Median age was 67 years old (36-92) and 48 (42.5%) patients had at least one comorbidity. The majority of the lesions were induced (30.7%) or repeated oligoprogressive (12.7%) metastases. 98 lesions were treated with more than one daily fraction (mainly 50 Gy in 5 fractions), while 52 were radiosurgery treatments (mainly 32 Gy). The treatment response at 3-4 months was evaluable in 147 lesions: complete response was 32.0%, partial response 17.0%, and stable disease 32.0%. Actuarial LC, DMFS, DFS, OS, and NEST-FS at 1 year were 75.8%, 37.7%, 34.9%, 78.7%, and 59.4% respectively; while actuarial LC, DMFS, DFS, OS, and NEST-FS at 2 years were 52.1%, 24.9%, 21.9%, 51.3%, and 36.8%, respectively. The achievement of complete response, synchronous oligometastases, and no treatment interruptions correlated with a more favorable outcomes. As per the toxicity profile, we registered only two acute and one late toxicity cases higher than grade 2. Stereotactic treatment for liver metastases seems to be a safe and promising option in terms of local control. The best results in term of outcomes have been obtained in patients with complete response, synchronous oligometastases, favorable histology, and no treatment interruptions.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":" ","pages":"667-678"},"PeriodicalIF":4.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Transcriptomic characterization of the histopathological growth patterns in breast cancer liver metastases. 乳腺癌肝转移组织病理学生长模式的转录组学特征分析

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-10-01 Epub Date: 2024-03-29 DOI: 10.1007/s10585-024-10279-1

Sophia Leduc, Ha-Linh Nguyen, François Richard, Gitte Zels, Amena Mahdami, Maxim De Schepper, Marion Maetens, Anirudh Pabba, Joris Jaekers, Emily Latacz, Ali Bohlok, Evy Vanderheyden, Thomas Van Brussel, Bram Boeckx, Rogier Schepers, Diether Lambrechts, Luc Dirix, Denis Larsimont, Sophie Vankerckhove, Valerio Lucidi, Baki Topal, Imane Bachir, Vincent Donckier, Giuseppe Floris, Peter Vermeulen, Christine Desmedt

{"title":"Transcriptomic characterization of the histopathological growth patterns in breast cancer liver metastases.","authors":"Sophia Leduc, Ha-Linh Nguyen, François Richard, Gitte Zels, Amena Mahdami, Maxim De Schepper, Marion Maetens, Anirudh Pabba, Joris Jaekers, Emily Latacz, Ali Bohlok, Evy Vanderheyden, Thomas Van Brussel, Bram Boeckx, Rogier Schepers, Diether Lambrechts, Luc Dirix, Denis Larsimont, Sophie Vankerckhove, Valerio Lucidi, Baki Topal, Imane Bachir, Vincent Donckier, Giuseppe Floris, Peter Vermeulen, Christine Desmedt","doi":"10.1007/s10585-024-10279-1","DOIUrl":"10.1007/s10585-024-10279-1","url":null,"abstract":"Metastatic breast cancer (mBC) remains incurable and liver metastases (LM) are observed in approximately 50% of all patients with mBC. In some cases, surgical resection of breast cancer liver metastases (BCLM) is associated with prolonged survival. However, there are currently no validated marker to identify these patients. The interactions between the metastatic cancer cells and the liver microenvironment result in two main histopathological growth patterns (HGP): replacement (r-HGP), characterized by a direct contact between the cancer cells and the hepatocytes, and desmoplastic (d-HGP), in which a fibrous rim surrounds the tumor cells. In patients who underwent resection of BCLM, the r-HGP is associated with a worse postoperative prognosis than the d-HGP. Here, we aim at unraveling the biological differences between these HGP within ten patients presenting both HGP within the same metastasis. The transcriptomic analyses reveal overexpression of genes involved in cell cycle, DNA repair, vessel co-option and cell motility in r-HGP while angiogenesis, wound healing, and several immune processes were found overexpressed in d-HGP LM. Understanding the biology of the LM could open avenues to refine treatment of BC patients with LM.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":" ","pages":"699-705"},"PeriodicalIF":4.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11499425/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140317902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project. Pembrolizumab在晚期上尿路上皮癌患者中的应用：来自ARON-2项目的真实世界研究。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-10-01 Epub Date: 2024-06-08 DOI: 10.1007/s10585-024-10296-0

Alessandro Rizzo, Sebastiano Buti, Patrizia Giannatempo, Samer Salah, Javier Molina-Cerrillo, Francesco Massari, Ray Manneh Kopp, Ondřej Fiala, Luca Galli, Zin W Myint, Deniz Tural, Andrey Soares, Renate Pichler, Alessia Mennitto, Halima Abahssain, Fabio Calabrò, Fernando Sabino M Monteiro, Anna Albano, Veronica Mollica, Giulia Claire Giudice, Hideki Takeshita, Matteo Santoni

{"title":"Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project.","authors":"Alessandro Rizzo, Sebastiano Buti, Patrizia Giannatempo, Samer Salah, Javier Molina-Cerrillo, Francesco Massari, Ray Manneh Kopp, Ondřej Fiala, Luca Galli, Zin W Myint, Deniz Tural, Andrey Soares, Renate Pichler, Alessia Mennitto, Halima Abahssain, Fabio Calabrò, Fernando Sabino M Monteiro, Anna Albano, Veronica Mollica, Giulia Claire Giudice, Hideki Takeshita, Matteo Santoni","doi":"10.1007/s10585-024-10296-0","DOIUrl":"10.1007/s10585-024-10296-0","url":null,"abstract":"Upper tract urothelial carcinoma (UTUC) accounts for the 5-10% of all urothelial carcinomas (UCs). In this analysis, we reported the real-world data from the ARON-2 study (NCT05290038) on the efficacy of pembrolizumab in patients with UTUC who recurred or progressed after platinum-based chemotherapy. Medical records of patients with metastatic UTUC treated with pembrolizumab as second-line therapy were reviewed from 34 institutions in 14 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall response rate (ORR). Univariate and multivariate analyses were used to explore the association of variables of interest with OS and PFS. 235 patients were included in our analysis. Median OS was 8.6 months (95% CI 6.6-12.1), the 1 year OS rate was 43% while the 2 years OS rate 29%. The median PFS was 5.1 months (95% CI 3.9-6.9); 46% of patients were alive at 6 months, 34% at 12 months and 25% at 24 months. According to RECIST 1.1, 18 patients (8%) experienced complete response (CR), 57 (24%) partial response (PR), 44 (19%) stable disease (SD), and 116 (49%) progressive disease (PD), with an ORR of 32%. Our study confirms the effectiveness of pembrolizumab in patients pretreated with a platinum-based combination, irrespective of their sensitivity to the first-line treatment and of their histology. In addition, we emphasized the limited benefit of the treatment with pembrolizumab in patients with hepatic metastases and poor ECOG performance status.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":" ","pages":"655-665"},"PeriodicalIF":4.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141293221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

UBTF mediates activation of L3MBTL2 to suppress NISCH expression through histone H2AK119 monoubiquitination modification in breast cancer. UBTF 在乳腺癌中通过组蛋白 H2AK119 单泛素化修饰介导 L3MBTL2 的激活以抑制 NISCH 的表达。

IF 4.2 3区医学

Clinical & Experimental Metastasis Pub Date : 2024-10-01 Epub Date: 2024-06-27 DOI: 10.1007/s10585-024-10299-x

Kun Chen, Yun Dong, Gaojian He, Xuefeng He, Meitong Pan, Xuemei Huang, Xiaolan Yu, Jiyi Xia

{"title":"UBTF mediates activation of L3MBTL2 to suppress NISCH expression through histone H2AK119 monoubiquitination modification in breast cancer.","authors":"Kun Chen, Yun Dong, Gaojian He, Xuefeng He, Meitong Pan, Xuemei Huang, Xiaolan Yu, Jiyi Xia","doi":"10.1007/s10585-024-10299-x","DOIUrl":"10.1007/s10585-024-10299-x","url":null,"abstract":"Lethal(3)malignant brain tumor-like protein 2 (L3MBTL2) has been related to transcriptional inhibition and chromatin compaction. Nevertheless, the biological functions and mechanisms of L3MBTL2 are undefined in breast cancer (BRCA). Here, we revealed that L3MBTL2 is responsible for the decline of Nischarin (NISCH), a well-known tumor suppressor, in BRCA, and explored the detailed mechanism. Knockdown of L3MBTL2 reduced monoubiquitination of histone H2A at lysine-119 (H2AK119ub), leading to reduced binding to the NISCH promoter and increased expression of NISCH. Meanwhile, the knockdown of L3MBTL2 decreased proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) of BRCA cells, and increased apoptosis, which were abated by NISCH knockdown. Nucleolar transcription factor 1 (UBTF) induced the transcription of L3MBTL2 in BRCA, and the suppressing effects of UBTF silencing on EMT in BRCA cells were also reversed by NISCH knockdown. Knockdown of UBTF slowed tumor progression and attenuated lung tumor infiltration, whereas simultaneous knockdown of NISCH accelerated EMT and increased tumor lung metastasis. Taken together, our results show that L3MBTL2, transcriptionally activated by UBTF, exerts oncogenic functions in BRCA, by catalyzing H2AK119Ub and reducing expression of NISCH.","PeriodicalId":10267,"journal":{"name":"Clinical & Experimental Metastasis","volume":" ","pages":"791-805"},"PeriodicalIF":4.2,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141455629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0